Has Tran Pham received payments from drug or device companies?

Yes. Drug and device makers reported $1,962 in general payments to Tran Pham across 93 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Tran Pham did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Tran Pham come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Tran Pham

Family · Slidell, LANPI 1164014981

Payments from drug & device makers

$1,962in general payments, 2019–2025

Across 93 payments — averaging $21.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$437
Axsome Therapeutics, Inc.$292
Amgen$259
Corcept Therapeutics$215
Lilly USA, LLC$165
Exact Sciences$118
plus $476 from 14 others

What the payments were for

Food & beverage$1,962100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	18	$437
Axsome Therapeutics, Inc.	5	$292
Amgen	22	$259
Corcept Therapeutics	5	$215
Lilly USA, LLC	10	$165
Exact Sciences	6	$118
Bayer	4	$79
Merck	6	$77
Astellas Pharma US Inc	3	$77
Novo Nordisk	3	$49
Viiv Healthcare Company	1	$32
Organon	2	$27
Phadia US Inc.	1	$21
Gilead	1	$20
Kowa Pharmaceuticals America, Inc.	1	$18
Pfizer	1	$17
Braeburn Inc.	1	$16
Alkermes, Inc.	1	$16
Sumitomo Pharma America, Inc.	1	$14
Global Blood Therapeutics, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VRAYLAR$215
Auvelity$214
Korlym$147
Otezla$100

How this compares

$1,962 in reported general payments places this provider in the 75th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	32	$38,532
JardianceEmpagliflozin	19	$16,680
MounjaroTirzepatide	14	$14,897
Repatha SureclickEvolocumab	20	$10,887
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	14	$10,411
PremarinEstrogens, Conjugated	11	$2,270
Atorvastatin Calcium	137	$621
Albuterol Sulfate HfaAlbuterol Sulfate	21	$430
Fluticasone Propionate	17	$261
Amlodipine Besylate	83	$247
Levothyroxine Sodium	38	$241
Gabapentin	30	$232
Famotidine	12	$219
Losartan Potassium	28	$204
Ibuprofen	33	$203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Novo NordiskOzempic	$49	$38,53232 claims
Lilly USA, LLCMounjaro	$165	$14,89714 claims
PfizerPremarin	$17	$2,27011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,610 family providers in Louisiana.